Press coverage about CareFusion (NYSE:CFN) has trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CareFusion earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned news headlines about the healthcare company an impact score of 46.4660388277976 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of CareFusion (NYSE CFN) remained flat at $$59.94 during trading on Wednesday. The firm has a market cap of $12,240.00 and a price-to-earnings ratio of 25.51.

ILLEGAL ACTIVITY NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/01/10/carefusion-cfn-receives-media-impact-rating-of-0-22.html.

CareFusion Company Profile

CareFusion Corporation is a global medical technology company. The Company operates in two business segments: Medical Systems and Procedural Solutions. The Company’s primary product brands include: Alaris intravenous (IV) infusion systems; Pyxis and Rowa automated medication dispensing and supply management systems; AVEA, Vela and LTV Series respiratory ventilators; ChloraPrep skin antiseptic products; MaxGuard, MaxPlus, MaxZero, SmartSite and Texium needle-free IV infusion valves, administration sets and accessories; V.

Receive News & Ratings for CareFusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareFusion and related companies with MarketBeat.com's FREE daily email newsletter.